Research
And Grants
Note: When clicking the "Submit Grant Application" button below you will be redirected to SnapGrant.com to complete the application process.
Submit Grant ApplicationThe Cure Starts Now has funded $25,966,182 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 173 grants at over 100 hospitals in 29 countries.
Note: All Grants Are U.S. Funded Through 2018
Children's National Medical Center – $200,000
$200,000.00
December 2025
“Targeted and Tuned: GPNMB/B7H3 Dual-Targeting CAR T-Cells With Focused Ultrasound for Potent Immunotherapy in Pediatric Gliomas
Seattle Children’s Hospital – $1,000,000 (Installment 1 of 4)
$250,000.00
September 2025
Augmentation of the tumor immune microenvironment to enhance B7-H3 CAR T cell efficacy against diffuse midline glioma
Princess Maxima Center – $50,000
$50,000.00
July 2025
Monitoring Nanobody-Based B7H3 CAR-T Cell Behavior and Efficacy in Diffuse Midline Glioma
Johns Hopkins Hospital – $100,000
$100,000.00
December 2024
Leveraging Epigenetic Alterations for Therapy of Diffuse Midline Glioma
CONNECT Consortium (TarGeT 2025) - $32,230 USD / $50,000 AUD
$32,230.00
December 2024
TarGeT 2025
CONNECT Consortium (TarGeT 2026) - $32,230 USD / $50,000 AUD
$32,230.00
December 2024
TarGeT 2026
CONNECT Consortium (TarGeT 2027) - $6,445 USD / $10,000 AUD
$6,445.00
December 2024
TarGeT 2027
Children’s Hospital of Philadelphia – $100,000
$100,000.00
December 2024
Cytokine Signaling in Diffuse Midline Glioma to Enhance GD2-Directed CAR T Cell Trafficking
UNC Eshelman School of Pharmacy – $50,000
$50,000.00
December 2024
Leveraging Open Science and Collaboration to Identify Clinical Quality ALK2 Inhibitors for DIPG
Murdoch Children's Research Institute – $100,000 USD / $156,914 AUD
$100,000.00
December 2024
Harnessing Developmental Neurobiology to Reprogram the Cell of Origin of Diffuse Midline Gliomas
Children’s Cancer Institute – $70,400 USD / $110,467 AUD
$70,400.00
December 2024
A Novel Formulation to Allow the Simultaneous Targeting of MYC Expression and Copper Chelation to Treat DIPG Tumor and Overcome Multidrug Resistance
The Institute for Medical Research Israel-Canada – $40,000 USD / 143,580 INS
$40,000.00
December 2024
CXCR1/2 Signaling Pathway: A Role in the Invasive Mechanism of DIPG
Children's Healthcare of Atlanta – $100,000
$100,000.00
November 2024
Radiation Resistance in Medulloblastoma
University of Texas Health Science Center at San Antonio – $100,000
$100,000.00
November 2024
Targeting Metabolic Vulnerabilities for Treating Medulloblastoma
University of Texas Health Science Center at San Antonio – $50,000
$50,000.00
November 2024
Targeting RRNA Modification and SNORNA Function, A Novel Concept to Treat Aggressive Medulloblastoma